| 41. |
|
|
| 42. |
|
|
| 43. |
- Kim, Won Keun, et al.
(författare)
-
Outcomes and performance of the ACURATE neo2 transcatheter heart valve in clinical practice : one-yearresults of the ACURATE neo2 PMCF Study
- 2024
-
Ingår i: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. - 1969-6213. ; 20:1, s. 85-94
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Transcatheter aortic valve implantation is an effective treatment for patients with aortic stenosis; however, complications related to paravalvular leakage (PVL) persist, including increased risk of mortality, cardiovascular mortality, and rehospitalisation. AIMS: We sought to evaluate the clinical outcomes and valve performance at 1 year in patients with severe aortic stenosis treated with the ACURATE neo2 valve in a post-market clinical setting. METHODS: Valve Academic Research Consortium-2 safety events were assessed up to 1 year. Independent core laboratories evaluated echocardiographic measures of valve performance and hypoattenuated leaflet thickening (HALT; as measured by four-dimensional computed tomography). RESULTS: The study enrolled 250 patients (64% female; mean age: 81 years; baseline Society of Thoracic Surgeons risk score: 2.9±2.0%); 246 patients were implanted with ACURATE neo2. All-cause mortality was 0.8% at 30 days and 5.1% at 1 year. The 1-year rates for stroke and disabling stroke were 3.0% and 1.3%, respectively. Overall, HALT of >50% leaflet involvement of at least one leaflet was present in 9% of patients at 30 days and in 12% of patients at 1 year. No association was observed between the presence of HALT and 1-year clinical or haemodynamic outcomes. Early haemodynamic improvements were maintained up to 1 year (mean aortic valve gradient: 47.6±14.5 mmHg at baseline, 7.6±3.2 mmHg at 1 year; mean aortic valve area: 0.7±0.2 cm2 at baseline, 1.7±0.4 cm2 at 1 year). At 1 year, 99% of patients had mild or no/trace PVL (<1% had moderate PVL; no patient had severe PVL). CONCLUSIONS: The study outcomes confirm favourable performance and safety up to 1 year in patients treated with ACURATE neo2 in routine clinical practice. (ClinicalTrials.gov: NCT04655248).
|
|
| 44. |
|
|
| 45. |
- Kimblad, Per Ola, et al.
(författare)
-
Percutaneous transvenous mitral annuloplasty (PTMA) with the Viking device reduces pacing-induced mitral regurgitation.
- 2005
-
Ingår i: EuroIntervention. - 1969-6213. ; 1:3, s. 346-351
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives: The new percutaneous mitral annuloplasty Viking device was evaluated in surviving sheep with pacing-induced mitral regurgitation. Methods and results: Twenty sheep were subjected to rapid ventricular pacing for one to three months, leading to cardiomyopathy and mitral regurgitation. Device implantation could be successfully performed in 11 of these animals after pacemaker treatment for 64′7 days. The device-related procedure time was 12′2 min. The mean follow-up time was 58′8 days after implantation of the device. Mitral annulus septolateral diameter was significantly reduced after insertion of the device, from 35′1 mm before implantation to 30′1 mm at the final follow up intracardiac echocardiography (P= 0.0097). The degree of mitral regurgitation (on a scale from 0 to 4) was 2.6′0.2 before device implantation and decreased to 0.8′0.2 after treatment (P= 0.0039), and the vena contracta was reduced from 7′0.4 mm to 3′0.8 mm (P= 0.0019). Angiography showed no signs of impairment of the coronary arteries. No thrombosis was observed. Conclusions: These results indicate that the septa-lateral diameter of the mitral annulus, and the degree of experimentally induced mitral regurgitation, can be significantly reduced with a percutaneous catheter technique in surviving sheep.
|
|
| 46. |
|
|
| 47. |
|
|
| 48. |
- Kreutzer, Martin, et al.
(författare)
-
Patent coronary artery and myocardial infarction in the era of primary angioplasty : assessment of an old problem in a new setting with data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
- 2010
-
Ingår i: EuroIntervention. - 1969-6213. ; 6:5, s. 590-595
-
Tidskriftsartikel (refereegranskat)abstract
- Aims: The purpose of this study was to evaluate factors that contribute to a patent IRA (infarct - related artery) and the prognostic impact of a patent IRA in patients with ST-elevation myocardial infarction.Methods and results: Using the Swedish angiography and angioplasty registry (SCAAR) we included all patients with STEMI and one-vessel coronary artery disease who underwent primary PCI of the culprit lesion only from May 2005 to December 2007. A patent IRA was found in 1,104 of 3,284 patients. Patients with an occluded IRA had significantly increased 7-day mortality (HR, 3.03, 95% CI 1.68-5.46, P<0.001). The incidence of an occluded IRA increased with higher age, in patients over 80 years of age (OR, 1.23, 95% CI; 0.92-1.64), lower in patients on lipid-lowering drugs (OR, 0.68, 95% CI; 0.54-0.86) and lower in patients pre-treated with heparin (OR 0.71, 95% CI; 0.60-0.83) or GPIIb/IIIa receptor blockade (OR 0.77, 95% CI; 0.61-0.97). Treatment with acetylsalicylic acid or clopidogrel had no effect on IRA patency.Conclusions: IRA patency was associated with a lower 7-day mortality. Older STEM I patients and patients not taking lipid-lowering drugs or pre-treated with heparin or GPIIb/IIIa receptor blockers seem to constitute risk groups for having an occluded IRA.
|
|
| 49. |
|
|
| 50. |
|
|
